Financial reports
10-K
2018 FY
Annual report
7 Mar 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
10-Q
2018 Q1
Quarterly report
8 May 18
10-K
2017 FY
Annual report
9 Mar 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
2 Aug 17
10-Q
2017 Q1
Quarterly report
8 May 17
10-K
2016 FY
Annual report
9 Mar 17
10-Q
2016 Q3
Quarterly report
1 Nov 16
Current reports
8-K
Completion of Acquisition or Disposition of Assets
23 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 19
8-K
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
15 Mar 19
8-K
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
7 Mar 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Jan 19
8-K
To be effected by anall-stock transaction plus issuance of Contingent Value Rights (“CVRs”); completion expected H1 2019
6 Dec 18
8-K
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
1 Nov 18
8-K
Other Events
17 Oct 18
8-K
Departure of Directors or Certain Officers
1 Oct 18
8-K
OncoMed Provides Update on Navicixizumab Partnership
20 Sep 18
Registration and prospectus
15-12B
Securities registration termination
3 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
25-NSE
Exchange delisting
23 Apr 19
425
Business combination disclosure
17 Apr 19
425
Business combination disclosure
15 Mar 19
Proxies
DEFM14A
Proxy related to merger
20 Mar 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
13 Apr 17
DEFA14A
Additional proxy soliciting materials
13 Apr 17
DEF 14A
Definitive proxy
29 Apr 16
DEFA14A
Additional proxy soliciting materials
29 Apr 16
DEF 14A
Definitive proxy
24 Apr 15
DEFA14A
Additional proxy soliciting materials
24 Apr 15
DEFA14A
Additional proxy soliciting materials
29 May 14
Other
CT ORDER
Confidential treatment order
21 Aug 18
EFFECT
Notice of effectiveness
20 Jun 18
CT ORDER
Confidential treatment order
13 Jun 18
CT ORDER
Confidential treatment order
12 Jun 17
CT ORDER
Confidential treatment order
14 Apr 17
CT ORDER
Confidential treatment order
13 Dec 16
CT ORDER
Confidential treatment order
15 Mar 16
CT ORDER
Confidential treatment order
23 Nov 15
EFFECT
Notice of effectiveness
22 Jul 15
CORRESP
Correspondence with SEC
20 Jul 15
Ownership
SC 13D/A
OncoMed Pharmaceuticals Inc
26 Apr 19
4
Alicia J. Hager
23 Apr 19
4
JONATHAN D ROOT
23 Apr 19
4
JACK W LASERSOHN
23 Apr 19
4
John A. Lewicki
23 Apr 19
4
DEEPIKA PAKIANATHAN
23 Apr 19
4
Yvonne Li
23 Apr 19
4
Robert Stagg
23 Apr 19
4
PERRY A KARSEN
23 Apr 19
SC 13D
OncoMed Pharmaceuticals Inc
15 Mar 19